Targeting MDSCs enhance therapeutic vaccination responses against lung cancer

OncoImmunology

Volumn 1, Issue 9, 2012, Pages 1650-1651

  Srivastava, Minu K ^a,b   Dubinett, Steven ^a,b   Sharma, Sherven ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Immune suppression; Immunotherapy; Lung cancer; Myeloid derived suppressor cells

Indexed keywords

CD11B ANTIGEN; CD14 ANTIGEN; CD15 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; CXCL9 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HLA DR ANTIGEN; INTERLEUKIN 4 RECEPTOR ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; VASCULOTROPIN A;

ANTIGEN EXPRESSION; EFFECTOR CELL; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; LEWIS CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MYELOID DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; NONHUMAN; NOTE; PRIORITY JOURNAL; SUPPRESSOR CELL; T CELL DEPLETION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH;

EID: 84885720042     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.21970     Document Type: Note

References (8)

1. Young MR, Wright MA, Pandit R. Myeloid differentiation treatment to diminish the presence of immunesuppressive CD34+ cells within human head and neck squamous cell carcinomas. J Immunol 1997; 159:990-6
2. Kusmartsev SA, Ogreba VI. [Suppressor activity of bone marrow and spleen cells in C57Bl/6 mice during carcinogenesis induced by 7,12-dimethylbenz(a)anthracene]. Eksp Onkol 1989; 11:23-6.
3. Kusmartsev SA, Kusmartseva IN, Afanasyev SG, Cherdyntseva NV. Immunosuppressive cells in bone marrow of patients with stomach cancer. Adv Exp Med Biol 1998; 451:189-94
4. Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol 2011; 32:19-25
5. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005; 65:3044-8
6. Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 2010; 70:4335-45
7. Srivastava MK, Bosch JJ, Thompson JA, Ksander BR, Edelman MJ, Ostrand-Rosenberg S. Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloidderived suppressor cells. Cancer Immunol Immunother 2008; 57:1493-504
8. Srivastava MK, Zhu L, Harris-White M, Kar U, Huang M, Johnson MF, et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One 2012; 7:e40677